- Motley Fool•7 days ago
Belviq's weak sales weighed heavily on Arena's stock last year.
- Zacks•10 days ago
Puma Biotechnology, Inc. (PBYI) has expanded the fourth cohort of the phase II SUMMIT study evaluating its lead candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating HER2 mutation (basket study).
- Zacks•11 days ago
Vertex Pharmaceuticals Incorporated (VRTX) announced preliminary financial results for 2016 and issued a financial outlook for 2017 on Jan 8, ahead of a Jan 9 presentation at the JP Morgan healthcare conference in San Francisco.
ARNA : Summary for Arena Pharmaceuticals, Inc. - Yahoo Finance
Arena Pharmaceuticals, Inc. (ARNA)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||1.34 x 200|
|Ask||1.53 x 1600|
|Day's Range||1.35 - 1.39|
|52 Week Range||1.32 - 2.16|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-3.58|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|